Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Aly Diana I have never considered myself a gamer, but I was thrilled to discover that a mini-game embedded in Borderlands 3 is reaching its audience—scientists and non-scientists alike—to advance science. This idea struck me as nothing short of brilliant: low cost, high yield, and impactful on a massive scale. During this discovery period,
Read moreBy: Adhella Menur As a member of the INA-RESPOND Science team, I am thrilled with the acceptance of the first publication from our HIV study, entitled “A Prospective Observational Cohort Study of HIV Infection in Indonesia: Baseline Characteristics and One-Year Mortality” in the BMC Infectious Dis-eases journal. This paper provides valuable evidence for Indonesia and
Read moreBy: Meity Siahaan, Dedy Hidayat On December 4-5, 2024, a delegation from the Indonesian Ministry of Health (MoH) visited the United States National Institutes of Health (NIH) to strengthen existing collaborations and explore new opportunities in health research. This visit was an important step in strengthening bilateral cooperation in clinical research and capacity building between
Read moreBy: Aaron Neal INA-RESPOND has much to celebrate over the past year, and much to be excited for in 2025. Highlights from 2024 include the completion of the InVITE study, presentations at the annual Re-PORT tuberculosis (TB) meeting in Brazil, and the acceptance of key publications from HIV study (INA-PROACTIVE) and TB study (TRIPOD). Despite
Read moreBy: INA-RESPOND NSC Members and Secretariat New Year, New Hope! To move forward with strength, we must first reflect on the journey that has brought us here. Over the past 14 years, INA-RESPOND has grown into a center of excellence in infectious disease research in Indonesia. This achievement would not have been possible with-out the
Read moreBy: Aly Diana The time has come for me to delve into Bayesian inference—a topic I’ve managed to avoid for years. Although I’m far from an expert, I’ve started scratching the surface of this fascinating concept. Here’s my attempt to share what I’ve learned: basic, but hopefully useful. Bayesian inference is a powerful statistical tool
Read moreBy: Caleb Leonardo Halim Introduction: Understanding Middle Age Middle age typically refers to the stage of life be-tween 40 and 60 years old, marking the shift from early adulthood to the later stages of life. During this time, the body undergoes natural physical and psychological changes that can impact strength, stamina, and overall health. While
Read moreBy: Rizki Auliah Bakri, Dhiny Reskita Ayu, Muhammad Fiqhi Hardiansyah, Adhella Menur The growing threat of antimicrobial resistance (AMR) Antimicrobial resistance (AMR) has been acknowl-edged to be one of the top three major public health threats by the WHO. AMR is potentially the greatest public health threat of our time, surpas-sing COVID-19 due to its
Read moreBy: FNL Leadership The Clinical Monitoring Research Program Leadership are excited to share that we have launched a new virtual training series aimed at describing the essentials of rapid response clinical research in unique, resource-constrained environments. The Frederick National Laboratory Global Clinical Research Educational Modules (FNL GCREM) is a series of virtual training modules developed
Read moreTo collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
